87 results
To identify which brain regions are activated after intranasal application of insulin and how this affects peripheral metabolism.
1) To assess insulin sensitivity and response in critically ill septic neonates and children. 2) To determine protein balance in septic, critically ill children at baseline and during a Hyperinsulinemic Euglycemic Clamp, while receiving standard or…
The main objective of this study is to investigate the effects of a glucagon challenge on hepatic glucose production, abdominal subcutaneous glucose levels in type 2 diabetes patients with and without oral antidiabetics. In addition, endothelial…
To determine whether glucose, lipid and protein metabolism can be accurately measured using stable isotopes in the same patient on two occasions in a 48 hour interval.
Investigate effect of IF on insulin resistance and possible role acylcarinitin profiles and glycolipids
- To study the response of active glucagon-like peptide-1 (GLP1), Glucagon, Insulin, C-peptide and growth hormone (GH) and liver gluconeogenesis to a glucagon challenge in healthy volunteers- To study the expression of glucagon receptor mRNA in the…
Herewith, we present a research protocol that allows us to examine feasibility and safety of checkpoint blockade neoadjuvant to standard of care (SOC) in a patient population in need for improved clinical outcome and in tumors likely to respond to…
To evaluate the safety and toxicity of ACT and low-dose IFN-alpha plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that do not result in treatment termination are considered acceptable for…
Main objective of this phase 2 trial is to evaluate efficacy of nivolumab in symptomatic brain metastases of metastatic melanoma patients. In addition, the efficacy will be compared between patients with previously locally treated (e.g. surgery,…
To assess uptake of 18F-PD-L1 and 89Zr- nivolumab in tumor lesions.
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…
In Small Cell Lung Cancer patients the purpose of this study is to compare the overall survival of patients on Nivolumab with patients on Topotecan after they have been treated with platinum -based first line chemotherapy.
The primary objective is to evaluate if patients treated with chemo-radiotherapy and prophylactic cranial irradiation followed by consolidation treatment (nivolumab plus ipilimumab) have a better outcome in terms of progression-free survival (time…
The aim of the study is to compare overall survival (OS) and Blinded Independent Central Review (BICR)-assessed progression free survival (PFS), of nivolumab, and nivolumab in combination with ipilimumab, versus placebo in subjects with ED-SCLC…
Primary: To assess 6 month PFS rate of Nivolumab in combination with EGF816 in EGFR mutated NSCLC patients and of Nivolumab in combination with INC280 in patients with cMET positive NSCLC patientsSecondary: 1: To assess clinical activity of…
Primary objective: To assess the feasibility of the addition of nivolumab consolidation to standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B NSCLC, as defined by the rate of grade *3 pneumonitis (CTCAE V4.0) 6 months…
Primary Objective:The primary objective is to compare the incidence of drug-related Grade 3 - 5 AEs of N3I1 to N1I3 in subjects with previously untreated, unresectable or metastatic melanoma.Secondary Objective:• To evaluate the ORR, as determined…
We hypothesise that treatment with nivolumab will extend disease-free survival, compared with placebo, as adjuvant therapy in all randomized patients and in patients with PD-L1 expressing tumours (membranous staining in > 1%) who are at high…
Primary Objectives:• To compare progression free survival (PFS) as determined by blinded independent central review (BICR) and overall survival (OS) of nivolumab combined with ipilimumab to pemetrexed plus cisplatin or carboplatin regimen as first…
Primary Objective:The primary objective is to assess the safety and tolerability of BMS-986179 administered alone and/or in combination with nivolumab.Secondary objectives:* To characterize the PD activity of BMS-986179 administered alone and in…